1 2 3 4 5 6 7 8 9 UNITED STATES DISTRICT COURT 10 SOUTHERN DISTRICT OF CALIFORNIA 11 12 CAREY LOWE, individually and on Case No.: 3:23-cv-01657-H-BLM behalf of all others similarly situated, 13 ORDER: Plaintiff, 14 v. (1) DENYING MASON RAINES 15 MOTION FOR APPOINTMENT TANDEM DIABETES CARE INC., 16 AS LEAD PLAINTIFF AND JOHN F. SHERIDAN, BRIAN B. APPROVAL OF HIS SELECTION 17 HANSEN, AND LEIGH A. OF COUNSEL; VOSSELLER, 18 Defendants. (2) DENYING THE MARTEL 19 FAMILY’S MOTION FOR 20 APPOINTMENT AS LEAD PLAINTIFFS AND APPROVAL 21 OF THEIR SELECTION OF 22 COUNSEL; AND
23 (3) GRANTING THE MOVANTS’ 24 JOINT MOTION TO APPOINT CO-LEAD PLAINTIFFS AND CO- 25 LEAD COUNSEL 26 [Doc. Nos. 3, 4, 5.] 27 28 On November 7, 2023, Mason Raines (“Raines”) filed a motion for appointment as 1 lead plaintiff and for approval of his selection of lead counsel. (Doc. No. 3.) That same 2 day, Thomas O. Martel and Linna Rae Martel (collectively, the “Martel Family”) filed a 3 motion for appointment as lead plaintiffs and for approval of their selection of lead counsel. 4 (Doc. No. 4.) 5 On November 22, 2022, Raines and the Martel Family (together, “Movants”) filed 6 a joint motion for appointment as co-lead plaintiffs and for their respective selections of 7 counsel to serve as co-lead counsel. (Doc. No. 5.) Movants represent that their respective 8 counsel met-and-conferred with counsel for Defendants Tandem Diabetes Care Inc., John 9 F. Sheridan, Brian B. Hansen, and Leigh A. Vosseller (collectively, “Defendants”). (Id. at 10 3.) Movants state that Defendants take no position regarding Movants’ pending motions 11 for lead plaintiff, the joint motion for appointment as co-lead plaintiffs, and Movants’ 12 respective selections of co-lead counsel. (Id.) No other competing motions for lead 13 plaintiff have been filed. 14 A hearing on this matter was scheduled for December 11, 2023 at 10:30 a.m. The 15 Court, pursuant to its discretion under Local Rule 7.1(d)(1), determined the matter was 16 appropriate for resolution without oral argument, submitted the motions on the parties’ 17 papers, and vacated the hearing. (Doc. No. 6.) For the reasons set forth below, the Court 18 grants Movants’ joint motion for appointment as co-lead plaintiffs and approves their 19 selections for co-lead counsel. The Court denies Movants’ individual motions as moot. 20 (Doc. Nos. 3, 4.) 21 BACKGROUND 22 On September 8, 2023, Plaintiff Carey Lowe (“Plaintiff Lowe”), through his counsel 23 Levi & Korsinsky LLP (“Levi & Korsinsky”), filed a securities class action complaint 24 against Defendants Tandem Diabetes Care, Inc. (“Tandem” or the “Company”), John F. 25 Sheridan, Brian B. Hansen, and Leigh A. Vosseller. (Doc. No. 1, Compl.) The complaint 26 alleges that between August 3, 2022, and November 2, 2022, inclusive (the “Class 27 Period”), Defendants defrauded investors in violation of Sections 10(b) and 20(a) of the 28 Securities Exchange Act, 15 U.S.C. §§ 78j(b), 78t(a), and U.S. Securities and Exchange 1 Commission Rule 10b-5, 17 C.F.R. § 240.10b-5. Specifically, the complaint asserts that 2 during the Class Period, Defendants made materially false and/or misleading statements 3 regarding Tandem’s projected revenue and sales for the year ending in 2022. (Compl. ¶ 4 2.) Plaintiff Lowe claims Tandem investors incurred significant losses when Tandem 5 revised its 2022 forecast downward from a range of $835 million to $845 million to a range 6 of $800 to $805 million. Plaintiff Lowe represents that the Company’s announcement 7 caused Tandem’s common stock to decline drastically, dropping 30.4% from November 2, 8 2022 to November 3, 2022. (Id. ¶¶ 4–5.) 9 In response to a notice that was published after Plaintiff Lowe filed his class action 10 complaint, Raines and the Martel Family filed their motions to be appointed as lead 11 plaintiff and for approval of their selection of lead counsel. (Doc. Nos. 3, 4.) Raines alleges 12 he purchased 1,000 shares of Tandem stock during the Class Period and suffered financial 13 losses of approximately $12,232.67. (Doc. No. 3-4, Ex. B to Declaration of Adam M. 14 Apton (“Apton Decl.”).) The Martel Family alleges they purchased 455 shares of Tandem 15 during the Class Period and suffered financial losses of approximately $7,792. (Doc. No. 16 4-3, Ex. A to Declaration of Jennifer Pafiti (“Pafiti Decl.”).) On November 22, 2023, after 17 reviewing each other’s motions, Movants filed a joint motion to appoint themselves as co- 18 lead plaintiffs and to approve their respective selections of counsel as co-lead counsel. 19 (Doc. No. 5.) Movants represent that it will be in the best interests of the class for Movants 20 to serve as co-lead plaintiffs and for their respective selections of counsel to serve as co- 21 lead counsel in this action. (Id. at 3.) 22 DISCUSSION 23 I. Appointment of Co-Lead Plaintiffs 24 Under the Private Securities Litigation Reform Act (“PSLRA”), the district court 25 shall appoint as lead plaintiff “the member or members of the purported plaintiff class that 26 the court determines to be most capable of adequately representing the interests of class 27 members.” 15 U.S.C. § 78u-4(a)(3)(B)(i). The presumptively most adequate plaintiff is 28 the one who: (1) has either filed the complaint or brought a motion for appointment as lead 1 plaintiff in response to the publication of notice; (2) “has the largest financial interest in 2 the relief sought by the class;” and (3) “otherwise satisfies the requirements of Rule 23 of 3 the Federal Rules of Civil Procedure.” Id. § 78u-4(a)(3)(B)(iii)(I)(aa)–(cc). “In other 4 words, the district court must compare the financial stakes of the various plaintiffs and 5 determine which one has the most to gain from the lawsuit. It must then focus its attention 6 on that plaintiff and determine, based on the information he has provided in his pleadings 7 and declarations, whether he satisfies the requirements of Rule 23(a), in particular those of 8 ‘typicality’ and ‘adequacy.’” In re Cavanaugh, 306 F.3d 726, 730 (9th Cir. 2002) 9 (emphasis in original). Once established, this presumption may be rebutted only upon 10 proof that the presumptive lead plaintiff: (1) “will not fairly and adequately protect the 11 interests of the class; or” (2) “is subject to unique defenses that render such plaintiff 12 incapable of adequately representing the class.” 15 U.S.C. § 78u-4(a)(3)(B)(iii)(II)(aa)– 13 (bb). 14 The decision to appoint “co-lead plaintiffs is within the discretion of the [district] 15 [c]ourt.” Miller v. Ventro Corp., No. 01-CV-1287, 2001 WL 34497752, at *9 (N.D. Cal. 16 Nov. 28, 2001). Here, Movants assert that it is in the best interests of the class for Raines 17 and the Martel Family to join efforts and serve as co-lead plaintiffs. (Doc. No. 5 at 3.) The 18 Court agrees and exercises its discretion to appoint co-lead plaintiffs in this action so long 19 as (1) Movants are the presumptively most adequate plaintiff under the PSLRA’s three- 20 pronged test; and (2) the presumption is not rebutted. 21 A. Preliminary Procedural Requirements. 22 Pursuant to the PSLRA, no later than 20 days after filing a class action securities 23 complaint, a private plaintiff or plaintiffs must publish a notice advising members of the 24 purported plaintiff class of the pendency of the action, the claims asserted, and that any 25 member of the purported class may move the court to serve as lead plaintiff. 15 U.S.C.
Free access — add to your briefcase to read the full text and ask questions with AI
1 2 3 4 5 6 7 8 9 UNITED STATES DISTRICT COURT 10 SOUTHERN DISTRICT OF CALIFORNIA 11 12 CAREY LOWE, individually and on Case No.: 3:23-cv-01657-H-BLM behalf of all others similarly situated, 13 ORDER: Plaintiff, 14 v. (1) DENYING MASON RAINES 15 MOTION FOR APPOINTMENT TANDEM DIABETES CARE INC., 16 AS LEAD PLAINTIFF AND JOHN F. SHERIDAN, BRIAN B. APPROVAL OF HIS SELECTION 17 HANSEN, AND LEIGH A. OF COUNSEL; VOSSELLER, 18 Defendants. (2) DENYING THE MARTEL 19 FAMILY’S MOTION FOR 20 APPOINTMENT AS LEAD PLAINTIFFS AND APPROVAL 21 OF THEIR SELECTION OF 22 COUNSEL; AND
23 (3) GRANTING THE MOVANTS’ 24 JOINT MOTION TO APPOINT CO-LEAD PLAINTIFFS AND CO- 25 LEAD COUNSEL 26 [Doc. Nos. 3, 4, 5.] 27 28 On November 7, 2023, Mason Raines (“Raines”) filed a motion for appointment as 1 lead plaintiff and for approval of his selection of lead counsel. (Doc. No. 3.) That same 2 day, Thomas O. Martel and Linna Rae Martel (collectively, the “Martel Family”) filed a 3 motion for appointment as lead plaintiffs and for approval of their selection of lead counsel. 4 (Doc. No. 4.) 5 On November 22, 2022, Raines and the Martel Family (together, “Movants”) filed 6 a joint motion for appointment as co-lead plaintiffs and for their respective selections of 7 counsel to serve as co-lead counsel. (Doc. No. 5.) Movants represent that their respective 8 counsel met-and-conferred with counsel for Defendants Tandem Diabetes Care Inc., John 9 F. Sheridan, Brian B. Hansen, and Leigh A. Vosseller (collectively, “Defendants”). (Id. at 10 3.) Movants state that Defendants take no position regarding Movants’ pending motions 11 for lead plaintiff, the joint motion for appointment as co-lead plaintiffs, and Movants’ 12 respective selections of co-lead counsel. (Id.) No other competing motions for lead 13 plaintiff have been filed. 14 A hearing on this matter was scheduled for December 11, 2023 at 10:30 a.m. The 15 Court, pursuant to its discretion under Local Rule 7.1(d)(1), determined the matter was 16 appropriate for resolution without oral argument, submitted the motions on the parties’ 17 papers, and vacated the hearing. (Doc. No. 6.) For the reasons set forth below, the Court 18 grants Movants’ joint motion for appointment as co-lead plaintiffs and approves their 19 selections for co-lead counsel. The Court denies Movants’ individual motions as moot. 20 (Doc. Nos. 3, 4.) 21 BACKGROUND 22 On September 8, 2023, Plaintiff Carey Lowe (“Plaintiff Lowe”), through his counsel 23 Levi & Korsinsky LLP (“Levi & Korsinsky”), filed a securities class action complaint 24 against Defendants Tandem Diabetes Care, Inc. (“Tandem” or the “Company”), John F. 25 Sheridan, Brian B. Hansen, and Leigh A. Vosseller. (Doc. No. 1, Compl.) The complaint 26 alleges that between August 3, 2022, and November 2, 2022, inclusive (the “Class 27 Period”), Defendants defrauded investors in violation of Sections 10(b) and 20(a) of the 28 Securities Exchange Act, 15 U.S.C. §§ 78j(b), 78t(a), and U.S. Securities and Exchange 1 Commission Rule 10b-5, 17 C.F.R. § 240.10b-5. Specifically, the complaint asserts that 2 during the Class Period, Defendants made materially false and/or misleading statements 3 regarding Tandem’s projected revenue and sales for the year ending in 2022. (Compl. ¶ 4 2.) Plaintiff Lowe claims Tandem investors incurred significant losses when Tandem 5 revised its 2022 forecast downward from a range of $835 million to $845 million to a range 6 of $800 to $805 million. Plaintiff Lowe represents that the Company’s announcement 7 caused Tandem’s common stock to decline drastically, dropping 30.4% from November 2, 8 2022 to November 3, 2022. (Id. ¶¶ 4–5.) 9 In response to a notice that was published after Plaintiff Lowe filed his class action 10 complaint, Raines and the Martel Family filed their motions to be appointed as lead 11 plaintiff and for approval of their selection of lead counsel. (Doc. Nos. 3, 4.) Raines alleges 12 he purchased 1,000 shares of Tandem stock during the Class Period and suffered financial 13 losses of approximately $12,232.67. (Doc. No. 3-4, Ex. B to Declaration of Adam M. 14 Apton (“Apton Decl.”).) The Martel Family alleges they purchased 455 shares of Tandem 15 during the Class Period and suffered financial losses of approximately $7,792. (Doc. No. 16 4-3, Ex. A to Declaration of Jennifer Pafiti (“Pafiti Decl.”).) On November 22, 2023, after 17 reviewing each other’s motions, Movants filed a joint motion to appoint themselves as co- 18 lead plaintiffs and to approve their respective selections of counsel as co-lead counsel. 19 (Doc. No. 5.) Movants represent that it will be in the best interests of the class for Movants 20 to serve as co-lead plaintiffs and for their respective selections of counsel to serve as co- 21 lead counsel in this action. (Id. at 3.) 22 DISCUSSION 23 I. Appointment of Co-Lead Plaintiffs 24 Under the Private Securities Litigation Reform Act (“PSLRA”), the district court 25 shall appoint as lead plaintiff “the member or members of the purported plaintiff class that 26 the court determines to be most capable of adequately representing the interests of class 27 members.” 15 U.S.C. § 78u-4(a)(3)(B)(i). The presumptively most adequate plaintiff is 28 the one who: (1) has either filed the complaint or brought a motion for appointment as lead 1 plaintiff in response to the publication of notice; (2) “has the largest financial interest in 2 the relief sought by the class;” and (3) “otherwise satisfies the requirements of Rule 23 of 3 the Federal Rules of Civil Procedure.” Id. § 78u-4(a)(3)(B)(iii)(I)(aa)–(cc). “In other 4 words, the district court must compare the financial stakes of the various plaintiffs and 5 determine which one has the most to gain from the lawsuit. It must then focus its attention 6 on that plaintiff and determine, based on the information he has provided in his pleadings 7 and declarations, whether he satisfies the requirements of Rule 23(a), in particular those of 8 ‘typicality’ and ‘adequacy.’” In re Cavanaugh, 306 F.3d 726, 730 (9th Cir. 2002) 9 (emphasis in original). Once established, this presumption may be rebutted only upon 10 proof that the presumptive lead plaintiff: (1) “will not fairly and adequately protect the 11 interests of the class; or” (2) “is subject to unique defenses that render such plaintiff 12 incapable of adequately representing the class.” 15 U.S.C. § 78u-4(a)(3)(B)(iii)(II)(aa)– 13 (bb). 14 The decision to appoint “co-lead plaintiffs is within the discretion of the [district] 15 [c]ourt.” Miller v. Ventro Corp., No. 01-CV-1287, 2001 WL 34497752, at *9 (N.D. Cal. 16 Nov. 28, 2001). Here, Movants assert that it is in the best interests of the class for Raines 17 and the Martel Family to join efforts and serve as co-lead plaintiffs. (Doc. No. 5 at 3.) The 18 Court agrees and exercises its discretion to appoint co-lead plaintiffs in this action so long 19 as (1) Movants are the presumptively most adequate plaintiff under the PSLRA’s three- 20 pronged test; and (2) the presumption is not rebutted. 21 A. Preliminary Procedural Requirements. 22 Pursuant to the PSLRA, no later than 20 days after filing a class action securities 23 complaint, a private plaintiff or plaintiffs must publish a notice advising members of the 24 purported plaintiff class of the pendency of the action, the claims asserted, and that any 25 member of the purported class may move the court to serve as lead plaintiff. 15 U.S.C. § 26 78u-4(a)(3)(A)(i)–(I). Not later than 60 days after the date on which the notice is published, 27 any member of the purported class may move the court to serve as lead plaintiff of the 28 purported class. Id. § 78u-4(a)(3)(A)(i)(II). 1 Plaintiff Lowe filed this action in this Court on September 8, 2023. (Doc. No. 1.) 2 That same day, Levi & Korsinsky published a notice of the pendency of the present action 3 in Globe Newswire, a widely circulated national business-oriented wire service. (Doc. No. 4 3-5, Ex. C to Apton Decl.; Doc. No. 3-1 at 9.) Levi & Korsinsky timely published the 5 notice within 20 days after the filing of the complaint. The notice properly lists the claims 6 and the class period and advises the putative class members that they have 60 days from 7 the date of the notice—until November 7, 2023—to file a motion to seek appointment as 8 lead plaintiff in the present lawsuit. (Doc. No. 3-5, Ex. C to Apton Decl.) On November 9 7, 2023, Movants filed their motions for appointment as lead plaintiff and for approval of 10 their selections for lead counsel. (Doc. Nos. 3, 4.) Movants satisfied the sixty-day 11 requirement. Accordingly, the Court finds that the notice in this action satisfied the 12 PSLRA’s requirements, and Movants fulfilled the statutorily mandated procedural 13 requirements to be eligible for appointment as co-lead plaintiffs. 14 B. Movants Have Significant Financial Interests in the Litigation. 15 The PSLRA creates a presumption that the most capable plaintiff is the one who 16 “has the largest financial interest in the relief sought by the class,” but the PSLRA does not 17 specify a method to ascertain “financial interest.” 15 U.S.C. § 78u-4(a)(3)(B)(iii)(I)(bb). 18 The Ninth Circuit does not mandate a particular method either; however, it has indicated 19 that district courts “may select accounting methods that are both rational and consistently 20 applied.” Cavanaugh, 306 F.3d at 730 n.4. District courts often equate financial interest 21 with actual economic losses suffered. See Inchen Huang v. Depomed, Inc., 289 F. Supp. 22 3d 1050, 1052 (N.D. Cal. 2017) (“[A]pproximate losses in the subject securities is the 23 preferred measure.”) (citations omitted). 24 Movants have alleged a significant financial interest in the litigation. Raines states 25 that he purchased 1,000 shares of Tandem stock during the Class Period and suffered losses 26 of approximately $12,232.67. (Doc. No. 3-4, Ex. B to Apton Decl.) The Martel Family 27 allege they purchased 455 shares of Tandem stock during the Class Period and suffered 28 financial losses of approximately $7,792. (Doc. No. 4-3, Ex. A to Pafiti Decl.) Aggregated 1 together, Movants sustained approximately $20,024.67 in losses. Because no other 2 competing motion alleges a larger financial stake in the litigation, Movants are the 3 presumptive co-lead plaintiffs if they otherwise meet the requirements of Rule 23, and the 4 presumption is not rebutted. 5 C. Movants Satisfy the Typicality and Adequacy Requirements. 6 Federal Rule of Civil Procedure 23(a) requires that the class representative have 7 claims and defenses that are typical of the claims or defenses of the class and that a class 8 representative will fairly and adequately protect the interests of the class. 9 First, the presumptive lead plaintiff satisfies the typicality requirement when “the 10 presumptive lead plaintiff’s claim arise[s] from the same event or course of conduct giving 11 rise to the claims of other class members and [are] based on the same legal theory.” Foster 12 v. Maxwell Techs., Inc., No. 13-CV-00580-BEN-RBB, 2013 WL 5780424, at *5 (S.D. 13 Cal. Oct. 24, 2013) (citation omitted) (internal quotation marks omitted). The claims must 14 be “reasonably co-extensive with those of absent class members; they need not be 15 substantially identical.” Hanlon v. Chrysler Corp., 150 F.3d 1011, 1020 (9th Cir. 1998). 16 Here, like other class members, Movants allege they purchased Tandem stock during the 17 Class Period at prices artificially inflated by Defendants’ material misrepresentations 18 and/or omissions and as a result, suffered damages. (Doc. No. 3-1 at 12; Doc. No. 4-1 at 19 12–13.) Movants’ claims arise from the same events. Moreover, they base their claims on 20 the same legal theory as the claims that the other class members alleged in the complaint. 21 Thus, the Court finds that Movants satisfy the typicality requirement. 22 Second, representation is “fair” and “adequate” when the interests of the plaintiffs 23 and their counsel do not conflict with the interests of other class members, and the plaintiffs 24 and their counsel will prosecute the action vigorously on behalf of the class. Hanlon, 150 25 F.3d at 1020. In this case, it appears that Movants’ interests align with those of the other 26 class members. (Doc. No. 3-1 at 9, 12–13; Doc. No. 4-1 at 13–14.) Raines, for his part, 27 signed a sworn certification representing his willingness to serve and assume the 28 responsibilities of class representative. (Doc. No. 3-3, Ex. A to Apton Decl.; see also Doc. 1 No. 3-6, Declaration of Mason Raines, Ex. D to Apton Decl.) Likewise, the Martel Family 2 signed sworn certificates representing their willingness to serve as class representatives. 3 (Doc. No. 4-5, Ex. C to Pafiti Decl.) Further, the Martel Family’s joint declaration sets 4 forth their shared interest in prosecuting the case and their understanding of the fiduciary 5 obligations that accompany the role of lead plaintiff. (Doc. No. 4-6 ¶ 5, Ex. D to Pafiti 6 Decl.) Moreover, Movants have a substantial financial stake in the litigation, giving them 7 an incentive to litigate vigorously and to represent the class’s claims. There is no evidence 8 of any actual or potential conflict of interest between Movants and the other class members. 9 Movants state that they believe serving as co-lead plaintiffs is in the best interests of the 10 class. (Doc. No. 5 at 3.) Finally, Raines and the Martel Family’s retained counsel, Levi & 11 Korsinsky and Pomerantz LLP (“Pomerantz”), respectively, as discussed below, are well 12 experienced in complex securities class action litigation and can represent the interests of 13 the class. Therefore, the Court concludes that Movants are the presumptive co-lead 14 plaintiffs under the PSLRA. 15 D. The Presumption Has Not Been Rebutted. 16 The presumption that Movants are the most adequate co-lead plaintiffs may be 17 rebutted only upon proof by a member of the purported plaintiff class that they will not 18 fairly and adequately protect the interests of the class or are subject to unique defenses that 19 render them incapable of adequately representing the class. 15 U.S.C. § 78u- 20 4(a)(3)(B)(iii)(II)(aa)–(bb). The Court has not received any competing motions for lead 21 plaintiff from any member of the purported plaintiff class. Defendants take no position on 22 the motions pending before the Court. (Doc. No. 5 at 3.) Accordingly, the presumption 23 that Movants are the presumptive co-lead plaintiffs has not been rebutted. 24 Movants are the presumptive co-lead plaintiffs because they (1) timely moved for 25 appointment as lead plaintiffs in response to the notice; (2) have the largest financial 26 interest in the litigation; and (3) otherwise satisfy the requirements of Rule 23. As 27 discussed above, this presumption has not been rebutted. Accordingly, the Court grants 28 Movants’ joint motion for approval as co-lead plaintiffs and denies Movants’ individual 1 motions as moot. The Court appoints Mason Raines, Thomas O. Martel, and Linna Rae 2 Martel as co-lead plaintiffs. 3 II. Approval of Co-Lead Plaintiffs’ Selection of Co-Lead Counsel 4 Under the PSLRA, once the court has designated a lead plaintiff or co-lead plaintiffs, 5 that plaintiff “shall, subject to the approval of the court, select and retain counsel to 6 represent the class.” 15 U.S.C. § 78u-4(a)(3)(B)(v). If the lead plaintiff has made a 7 reasonable choice of counsel, the district court should generally defer to that choice. Cohen 8 v. U.S. Dist. Ct., 586 F.3d 703, 712 (9th Cir. 2009). 9 Here, Raines and the Martel Family ask the Court to approve their respective 10 selections of Levi & Korsinsky and Pomerantz to serve as co-lead counsel to represent the 11 class. On their firm resume, Levi & Korsinsky claim to be highly experienced in securities 12 litigation and class actions. (Doc. No. 3-7, Ex. E to Apton Decl.) They represent that they 13 have successfully prosecuted numerous securities litigations and securities fraud class 14 actions on behalf of shareholders and have served as lead or co-lead counsel in numerous 15 securities class action litigation matters, obtaining millions of dollars in recovery. (Id. at 16 6–8.) Pomerantz’s firm resume boasts similar skills, experiences, and accomplishments. 17 (Doc. No. 4-7, Ex. E to Pafiti Decl.) For example, Pomerantz cites numerous million- 18 dollar settlements obtained in class action securities litigation like this action as evidence 19 of their prowess in securities litigation. (Id. at 3–8.) Movants believe that it is in the best 20 interests of the class for their respective selections of counsel to serve as co-lead counsel. 21 (Doc. No. 5 at 3.) Considering the firms’ substantial experience in securities class action 22 litigation, the Court approves Movants respective choices of counsel, and appoints Levi & 23 Korsinsky and Pomerantz to serve as co-lead counsel. 24 CONCLUSION 25 For the reasons above, the Court GRANTS Movants’ joint motion to be appointed 26 as co-lead plaintiffs and approves their respective selections of counsel to serve as co-lead 27 counsel. (Doc. No. 5.) The Court DENIES Raines and the Martel Family’s individual 28 motions for lead plaintiff as moot. (Doc. Nos. 3, 4.) The Court ORDERS the following: ] 1. Plaintiffs Mason Raines, Thomas O. Martel, and Linna Rae Martel are 2 ||appointed to serve as Co-Lead Plaintiffs (“Co-Lead Plaintiffs”) under Section 3 ||}21D(a)(3)(B) of the Securities Exchange Act of 1934, 15 U.S.C. § 78u-4(a)(3)(B), as 4 ||amended by the Private Securities Litigation Reform Act of 1995, in the above-captioned 5 || action. 6 2. Co-Lead Plaintiffs’ selection of co-lead counsel is approved, and the Court 7 ||appoints Levi & Korsinsky LLP and Pomerantz LLP as Co-Lead Counsel for the class. 8 IT IS SO ORDERED. 9 || DATED: December 6, 2023 | | | ul | | | □ J 10 MARILYN 8. HUFF, Senior rict Judge 1] UNITED STATES DISTRICT COURT 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28